Newer oral and noninsulin therapies to treat type 2 diabetes mellitus
Copyright © 2016 Cleveland Clinic..
The pathophysiology of type 2 diabetes mellitus involves several biologic mechanisms and no single medication addresses them all. Most patients require more than one medication to adequately treat their diabetes, needing drugs with unique and complementary mechanisms of action to address and balance insulin and glucagon levels. In the past decade, several therapeutic drug classes have been developed for type 2 diabetes mellitus. Each provides therapeutic options with novel mechanisms of action to help clinicians achieve the goal of glucose homeostasis while controlling adverse events, especially reducing the risk of hypoglycemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Cleveland Clinic journal of medicine - 83(2016), 5 Suppl 1 vom: 02. Mai, Seite S18-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hermayer, Kathie L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.01.2018 Date Revised 19.01.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3949/ccjm.83.s1.04 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM260323608 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM260323608 | ||
| 003 | DE-627 | ||
| 005 | 20231224193141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3949/ccjm.83.s1.04 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0867.xml |
| 035 | |a (DE-627)NLM260323608 | ||
| 035 | |a (NLM)27176678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hermayer, Kathie L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newer oral and noninsulin therapies to treat type 2 diabetes mellitus |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2018 | ||
| 500 | |a Date Revised 19.01.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Cleveland Clinic. | ||
| 520 | |a The pathophysiology of type 2 diabetes mellitus involves several biologic mechanisms and no single medication addresses them all. Most patients require more than one medication to adequately treat their diabetes, needing drugs with unique and complementary mechanisms of action to address and balance insulin and glucagon levels. In the past decade, several therapeutic drug classes have been developed for type 2 diabetes mellitus. Each provides therapeutic options with novel mechanisms of action to help clinicians achieve the goal of glucose homeostasis while controlling adverse events, especially reducing the risk of hypoglycemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Dake, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cleveland Clinic journal of medicine |d 1996 |g 83(2016), 5 Suppl 1 vom: 02. Mai, Seite S18-26 |w (DE-627)NLM012620769 |x 1939-2869 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2016 |g number:5 Suppl 1 |g day:02 |g month:05 |g pages:S18-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3949/ccjm.83.s1.04 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2016 |e 5 Suppl 1 |b 02 |c 05 |h S18-26 | ||